uniQure (NASDAQ:QURE) Shares Gap Up Following Analyst Upgrade

uniQure N.V. (NASDAQ:QURE)’s share price gapped up prior to trading on Wednesday after Royal Bank Of Canada raised their price target on the stock from $35.00 to $65.00. The stock had previously closed at $26.99, but opened at $43.55. Royal Bank Of Canada currently has an outperform rating on the stock. uniQure shares last traded at $47.4490, with a volume of 6,117,597 shares trading hands.

Other equities analysts also recently issued research reports about the company. The Goldman Sachs Group increased their price target on uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating on shares of uniQure in a research note on Thursday. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $15.00 to $60.00 in a research report on Monday, March 9th. Sanford C. Bernstein lowered uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Finally, Wolfe Research assumed coverage on shares of uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating on the stock. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $58.92.

Insider Buying and Selling

In other news, insider Jeannette Potts sold 5,237 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $27.67, for a total value of $144,907.79. Following the transaction, the insider owned 133,246 shares in the company, valued at $3,686,916.82. This trade represents a 3.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Madhavan Balachandran sold 10,000 shares of uniQure stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $27.85, for a total value of $278,500.00. Following the completion of the sale, the director directly owned 43,254 shares in the company, valued at $1,204,623.90. This represents a 18.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 101,054 shares of company stock worth $2,655,791 in the last quarter. 4.65% of the stock is owned by insiders.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: FDA feedback now suggests uniQure can move ahead with a BLA submission for AMT-130 using existing mid-stage data, significantly improving the regulatory timeline. Reuters
• Positive Sentiment: Cantor Fitzgerald upgraded uniQure to Overweight and raised its price target, reflecting improved confidence in the company’s Huntington’s program. Seeking Alpha
• Positive Sentiment: Barclays also upgraded the stock and lifted its target, adding to the wave of bullish analyst sentiment after the FDA development. Benzinga
• Neutral Sentiment: There were insider sales disclosed this week, including transactions by directors and executives, but these appear to be routine filings and are being overshadowed by the FDA-driven rally.

Institutional Investors Weigh In On uniQure

A number of large investors have recently modified their holdings of QURE. Jones Financial Companies Lllp raised its position in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares during the last quarter. CIBC Private Wealth Group LLC acquired a new position in uniQure during the third quarter worth about $50,000. Torren Management LLC acquired a new position in uniQure during the fourth quarter worth about $28,000. FNY Investment Advisers LLC grew its stake in uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 718 shares in the last quarter. Finally, IFP Advisors Inc purchased a new stake in uniQure during the 4th quarter valued at about $48,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

The company has a market cap of $2.92 billion, a price-to-earnings ratio of -13.30 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock’s fifty day simple moving average is $24.13 and its 200 day simple moving average is $22.03.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. As a group, analysts anticipate that uniQure N.V. will post -3.64 earnings per share for the current year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.